EE200300179A - Humaniseeritud LT-ß-R-i vastased antikehad - Google Patents

Humaniseeritud LT-ß-R-i vastased antikehad

Info

Publication number
EE200300179A
EE200300179A EEP200300179A EEP200300179A EE200300179A EE 200300179 A EE200300179 A EE 200300179A EE P200300179 A EEP200300179 A EE P200300179A EE P200300179 A EEP200300179 A EE P200300179A EE 200300179 A EE200300179 A EE 200300179A
Authority
EE
Estonia
Prior art keywords
antibodies
humanized anti
humanized
Prior art date
Application number
EEP200300179A
Other languages
English (en)
Estonian (et)
Inventor
A. Garber Ellen
Lyne Paul
W. Saldanha Jose
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of EE200300179A publication Critical patent/EE200300179A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200300179A 2000-10-13 2001-10-12 Humaniseeritud LT-ß-R-i vastased antikehad EE200300179A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (fr) 2000-10-13 2001-10-12 ANTICORPS HUMANISES ANTI-LT-β-R

Publications (1)

Publication Number Publication Date
EE200300179A true EE200300179A (et) 2003-08-15

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300179A EE200300179A (et) 2000-10-13 2001-10-12 Humaniseeritud LT-ß-R-i vastased antikehad

Country Status (25)

Country Link
US (2) US7429644B2 (fr)
EP (1) EP1326897A2 (fr)
JP (1) JP2004532608A (fr)
KR (1) KR20030041164A (fr)
CN (1) CN1547590A (fr)
AR (1) AR035352A1 (fr)
AU (2) AU2002211747B2 (fr)
BG (1) BG107802A (fr)
BR (1) BR0114646A (fr)
CA (1) CA2425809A1 (fr)
CZ (1) CZ20031307A3 (fr)
EA (1) EA006945B1 (fr)
EE (1) EE200300179A (fr)
GE (1) GEP20063752B (fr)
HU (1) HUP0302573A2 (fr)
IL (1) IL155340A0 (fr)
IS (1) IS6779A (fr)
MX (1) MXPA03003144A (fr)
NO (1) NO20031642L (fr)
NZ (1) NZ525793A (fr)
PL (1) PL366307A1 (fr)
SK (1) SK5672003A3 (fr)
TR (2) TR200300478T2 (fr)
WO (1) WO2002030986A2 (fr)
YU (1) YU28503A (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2491480A1 (fr) * 2002-07-01 2004-01-08 Biogen, Inc. Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
CA2511013A1 (fr) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques
WO2004058183A2 (fr) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agents recepteurs beta de la lymphotoxine combine a des agents chimiotherapeutiques
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
WO2005047327A2 (fr) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (fr) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Molecules de liaison multispecifiques comprenant des peptides de connexion
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
TWI422387B (zh) * 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
WO2012158818A2 (fr) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
WO2013012733A1 (fr) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Régions fc hétérodimères, molécules de liaison les comprenant, et méthodes associées
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CR20180097A (es) 2015-07-14 2018-05-25 Immunext Inc Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
EP3368090A1 (fr) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Conjugués de variants d'anticorps anti-facteur d et leurs utilisations
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3430058A4 (fr) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. Protéines de fusion à fab multispécifiques et leur utilisation
EP3847196A4 (fr) 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
WO2020132810A1 (fr) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Protéines multispécifiques de liaison à l'antigène pouvant se lier à cd19 et cd3, et leur utilisation
CA3164226A1 (fr) 2019-12-11 2021-06-17 Cilag Gmbh International Molecules de liaison multispecifiques comprenant des domaines de liaison ltbr et edb et leurs utilisations
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (fr) 2020-12-02 2022-06-09 Oncurious Nv Anticorps antagoniste de ccr8 en combinaison avec un anticorps agoniste du récepteur bêta de la lymphotoxine en thérapie contre le cancer
CN115594759B (zh) * 2021-07-08 2026-04-24 洛阳普泰生物技术有限公司 犬轮状病毒单克隆抗体对及其应用
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (fr) * 2022-05-11 2023-11-16 Pfizer Inc. Anticorps anti-récepteur de la lymphotoxine bêta et leurs procédés d'utilisation
CN120882754A (zh) 2023-04-07 2025-10-31 瑞泽恩制药公司 用淋巴毒素β受体激动剂治疗癌症的方法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025221728A2 (fr) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Molécules de liaison à ltbr et leurs utilisations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06501456A (ja) 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
EP0519596B1 (fr) 1991-05-17 2005-02-23 Merck & Co. Inc. Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
WO1994004679A1 (fr) * 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
CA2150249A1 (fr) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxine-.beta., complexes de lymphotoxine-.beta., preparations pharmaceutiques a base de ces substances et emploi therapeutique de ces preparations
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2319698A1 (fr) 1998-01-30 1999-08-05 Biogen, Inc. Traitement des lymphomes folliculaires a l'aide d'inhibiteurs de la voie de la lymphotoxine (lt)
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CA2491480A1 (fr) * 2002-07-01 2004-01-08 Biogen, Inc. Anticorps humanises diriges contre le recepteur de la lymphotoxine beta
WO2004058183A2 (fr) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agents recepteurs beta de la lymphotoxine combine a des agents chimiotherapeutiques
CA2511013A1 (fr) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Agonistes multivalents de recepteur beta de lymphotoxine et leurs applications therapeutiques

Also Published As

Publication number Publication date
IS6779A (is) 2003-04-11
US7429644B2 (en) 2008-09-30
AR035352A1 (es) 2004-05-12
YU28503A (sh) 2006-05-25
CN1547590A (zh) 2004-11-17
NO20031642L (no) 2003-06-13
HUP0302573A2 (hu) 2003-10-28
US20040058394A1 (en) 2004-03-25
TR200602095T2 (tr) 2007-02-21
MXPA03003144A (es) 2004-12-06
CA2425809A1 (fr) 2002-04-18
AU1174702A (en) 2002-04-22
EA006945B1 (ru) 2006-06-30
NZ525793A (en) 2008-04-30
KR20030041164A (ko) 2003-05-23
WO2002030986A2 (fr) 2002-04-18
JP2004532608A (ja) 2004-10-28
WO2002030986A3 (fr) 2003-03-13
TR200300478T2 (tr) 2004-10-21
BG107802A (bg) 2004-01-30
GEP20063752B (en) 2006-02-27
CZ20031307A3 (cs) 2003-10-15
AU2002211747B2 (en) 2007-11-29
SK5672003A3 (en) 2003-10-07
NO20031642D0 (no) 2003-04-10
IL155340A0 (en) 2003-11-23
EA200300464A1 (ru) 2003-10-30
PL366307A1 (en) 2005-01-24
US20090092601A1 (en) 2009-04-09
EP1326897A2 (fr) 2003-07-16
BR0114646A (pt) 2006-02-21

Similar Documents

Publication Publication Date Title
EE200300179A (et) Humaniseeritud LT-ß-R-i vastased antikehad
DE60222658D1 (de) Monoklonaler anti-cd-40-antikörper
IL156030A0 (en) Humanized antibodies
IS6982A (is) Mótefni gegn VLA-1
DK1501856T3 (da) Anti-HER2 antistofvarianter
NO20044347L (no) Anti-alfavbeta6-antistoff
IL166244A0 (en) Super humanized antibodies
IS2940B (is) Mótefni gegn CD40
DE50100900D1 (de) Fixierelement
EP1396500A4 (fr) Anticorps anti-trail-r
DE10085449T1 (de) Fixiervorrichtung
EE200300569A (et) CD44v6-spetsiifilised antikehad
DK1164375T3 (da) Assay til antitransglutaminaseantistoffer
FI20011055A0 (fi) Heveiiniä sitovat monoklonaaliset vasta-aineet
NO20011006D0 (no) Høy-affinitets antistoffer
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
ITPD20000192A0 (it) Anticorpi policlonali
DE60135621D1 (de) Fixiergerät
AR028262A1 (es) Anticuerpos especificos de fap-alfa humanos
DK1503799T3 (da) Immunogent, monoklonalt antistof
GB0030139D0 (en) Monoclonal antibody
GB0029846D0 (en) Monoclonal antibody
GB0003359D0 (en) Monoclonal antibodies
GB0008160D0 (en) Monoclonal antibodies
EA200201031A1 (ru) Двигательно-движительный комплекс

Legal Events

Date Code Title Description
HC1A Change of owner name